$0.00
(Market cap
$3 Mln
Revenue (TTM)
$7 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-79 Mln
-
ROE
-4.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
73,562,600
10 Years Aggregate
CFO
$-480.85 Mln
EBITDA
$-502.75 Mln
Net Profit
$-610.22 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aravive (ARAV)
| -67.7 | -66.9 | -74.1 | -98.0 | -80.7 | -61.4 | -- |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Aravive (ARAV)
| -90.6 | -39.7 | -61.2 | -58.7 | 288.4 | -73.1 | -85.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aravive (ARAV)
|
0.0 | 3.0 | 7.0 | -81.2 | -1,216.8 | -- | -- | 1.7 |
| 0.0 | 0.5 | 0.0 | -22.0 | -- | -- | -- | 0.4 | |
| 31.2 | 8,724.2 | 287.6 | -73.1 | -27.4 | -21.4 | -- | 15.5 | |
| 0.0 | 5.8 | 21.0 | -96.1 | -338.3 | -- | -- | 18.5 | |
| 0.0 | -- | 481.6 | -1,440.6 | -91.5 | -- | -- | 0.0 |
Shareholding Pattern
View DetailsAbout Aravive (ARAV)
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy... protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas. Read more
-
Executive Chairman
Dr. Fredric N. Eshelman Pharm.D.
-
Executive Chairman
Dr. Fredric N. Eshelman Pharm.D.
-
Headquarters
Houston, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aravive (ARAV)
What is the current share price of Aravive Inc (ARAV) Today?
The share price of Aravive Inc (ARAV) is $0.04 (NASDAQ) as of 07-Feb-2024 09:30 EDT. Aravive Inc (ARAV) has given a return of -80.74% in the last 3 years.
What is the current PB & PE ratio of Aravive Inc (ARAV)?
Since, TTM earnings of Aravive Inc (ARAV) is negative, P/E ratio is not available.
The P/B ratio of Aravive Inc (ARAV) is 1.73 times as on 07-Feb-2024, a 61 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.03
|
7.80
|
|
2021
|
-1.21
|
1.09
|
|
2020
|
-2.67
|
1.90
|
|
2019
|
-8.44
|
2.48
|
|
2018
|
-0.49
|
0.62
|
What is the 52 Week High and Low of Aravive Inc (ARAV)?
The 52-week high and low of Aravive Inc (ARAV) are Rs -- and Rs -- as of 17-May-2026.
What is the market cap of Aravive Inc (ARAV)?
Aravive Inc (ARAV) has a market capitalisation of $ 3 Mln as on 07-Feb-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Aravive Inc (ARAV)?
Before investing in Aravive Inc (ARAV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.